B7-H3 and B7x are highly expressed in human prostate cancer and associated with disease spread and poor outcome
Open accessThe DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
B7-H3 and B7x are recently discovered members of the B7-CD28 family thought to dampen peripheral immune responses via negative costimulation. We evaluated their potential expression in human prostate cancer using a large cohort of patients with 7 years of follow-up. We identified 823 patients with tissue available treated with radical prostatectomy between 1985 and 2003. Immunohistochemistry was performed on tissue microarray sections using anti-B7-H3 and -B7x. The percentage and intensity of immunoreactivity by tumor cells were blindly evaluated by two urological pathologists, and outcome analyses were conducted. Both B7-H3 and B7x were highly expressed; 93% and 99% of tumors had aberrant expression, respectively. The median percentage of tumor cells staining positive was 80% for each molecule. Strong intensity for B7-H3 and B7x was noted in 212 (26%) and 120 (15%) patients, respectively. Patients with strong intensity for B7-H3 and B7x were significantly more likely to have disease spread at time of surgery ( P < 0.001 and P = 0.005, respectively). Additionally, patients with strong intensity for B7-H3 and B7x were at significantly increased risk of clinical cancer recurrence ( P < 0.001 and P = 0.005) and cancer-specific death ( P = 0.004 and P = 0.04, respectively). To our knowledge, we present the largest investigation of B7 family molecules in a human malignancy and a previously undescribed evaluation of B7x in prostate cancer. B7-H3 and B7x are abundantly expressed in prostate cancer and associated with disease spread and poor outcome. Given the proposed immune-inhibitory mechanisms of B7-H3 and B7x, these molecules represent attractive targets for therapeutic manipulation in prostate cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“As a result, overexpression of B7H3 is associated with disease spread, including increased extracapsular extension and seminal vesicle invasion, as well as worse outcomes, including higher risk of metastatic recurrence or subsequent development of CRPC88.”
From The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer (2025) · cites this paper as [88]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Jemal, A., Siegel, R., Ward, E., Murray, T., Xu, J., & Thun, M. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.1.43 · Cited by 7,439
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Self-citationDong, H., Zhu, G., Tamada, K., & Chen, L. (1999) · Nature Medicine · doi:10.1038/70932 · Cited by 2,496
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Self-citationHamanishi, J., Mandai, M., Iwasaki, M., Okazaki, T., Tanaka, Y., Yamaguchi, K., Higuchi, T., Yagi, H., Takakura, K., Minato, N., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611533104 · Cited by 1,378
Co-inhibitory molecules of the B7–CD28 family in the control of T-cell immunity
Chen, L. (2004) · Nature Reviews Immunology · doi:10.1038/nri1349 · Cited by 1,257
Tumor Rejection After Direct Costimulation of CD8 + T Cells by B7-Transfected Melanoma Cells
Townsend, S. E., & Allison, J. P. (1993) · Science · doi:10.1126/science.7678351 · Cited by 1,136
Self-citationB7-H3: A costimulatory molecule for T cell activation and IFN-γ production
Chapoval, A. I., Ni, J., Lau, J. S., Wilcox, R. A., Flies, D. B., Liu, D., Dong, H., Sica, G. L., Zhu, G., Tamada, K., et al. (2001) · Nature Immunology · doi:10.1038/85339 · Cited by 1,015
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Hodi, F. S., Mihm, M. C., Soiffer, R. J., Haluska, F. G., Butler, M., Seiden, M. V., Davis, T., Henry-Spires, R., MacRae, S., Willman, A., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0830997100 · Cited by 1,006
Self-citation
Cited by
Items 101–200 of 420
Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks
Comiskey, M. C., Dallos, M. C., & Drake, C. G. (2018) · Current Oncology Reports · doi:10.1007/s11912-018-0712-z · Cited by 70
Mercier, I., Casimiro, M. C., Zhou, J., Wang, C., Plymire, C., Bryant, K. G., Daumer, K. M., Sotgia, F., Bonuccelli, G., Witkiewicz, A. K., et al. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2009.080882 · Cited by 70
Ji, J., Yu, F., Ji, Q., Li, Z., Wang, K., Zhang, J., Lu, J., Chen, L., E, Q., Zeng, Y., et al. (2012) · Hepatology · doi:10.1002/hep.25650 · Cited by 55
Host B7x Promotes Pulmonary Metastasis of Breast Cancer
Abadi, Y. M., Jeon, H., Ohaegbulam, K. C., Scandiuzzi, L., Ghosh, K., Hofmeyer, K. A., Lee, J. S., Ray, A., Gravekamp, C., & Zang, X. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1202439 · Cited by 69
Self-citationHe, C.-S., Liu, Y.-C., Xu, Z., Dai, P.-C., Chen, X., & Jin, D.-H. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000453175 · Cited by 69
The perspective of immunotherapy: new molecules and new mechanisms of action in immune modulation
Blank, C. U. (2014) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000054 · Cited by 68
Lei, X., Ou, Z., Yang, Z., Zhong, J., Zhu, Y., Tian, J., Wu, J., Deng, H., Lin, X., Yu, P., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2487 · Cited by 68
“Numerous studies have described B7-H3 overexpression in human malignancies, including melanoma (13), leukemia (14), breast cancer (15), prostate cancer (16), ovarian cancer (17), pancreatic cancer (18) and colorectal cancer (19).”
BackgroundTissue-specific expression of B7x protects from CD4 T cell–mediated autoimmunity
Wei, J., Loke, P., Zang, X., & Allison, J. P. (2011) · The Journal of Experimental Medicine · doi:10.1084/jem.20100639 · Cited by 67
Self-citation203/212Pb Theranostic Radiopharmaceuticals for Image-guided Radionuclide Therapy for Cancer
Li, M., Sagastume, E. A., Lee, D., McAlister, D. R., DeGraffenreid, A. J., Olewine, K. R., Graves, S. A., Copping, R., Mirzadeh, S., Zimmerman, B. E., et al. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327999200727190423 · Cited by 65
Chen, W., Liu, P., Wang, Y., Nie, W., Li, Z., Xu, W., Li, F., Zhou, Z., Zhao, M., & Liu, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076965 · Cited by 64
B7-H3 expression in breast cancer and upregulation of VEGF through gene silence
Sun, J., Guo, Y., Li, X., Zhang, Y., Gu, L., Wu, P., Bai, G., & Xiao, Y. (2014) · OncoTargets and Therapy · doi:10.2147/ott.s63424 · Cited by 63
B7-H3 immunoregulatory roles in cancer
Mortezaee, K. (2023) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2023.114890 · Cited by 62
Silencing of B7-H3 increases gemcitabine sensitivity by promoting apoptosis in pancreatic carcinoma
ZHAO, X., Zhang, G., Gan, W.-J., XIONG, F., Li, Z., Zhao, H., Zhu, D., Zhang, B., Zhang, X., & Li, D. (2013) · Oncology Letters · doi:10.3892/ol.2013.1118 · Cited by 62
B7-H3 Overexpression Predicts Poor Survival of Cancer Patients: A Meta-Analysis
Ye, Z., Zheng, Z., Li, X., Zhu, Y., Zhong, Z.-P., Peng, L., & Wu, Y. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000447859 · Cited by 63
Molecular imaging of T cell co-regulator factor B7-H3 with 89Zr-DS-5573a
Burvenich, I. J. G., Parakh, S., Lee, F.-T., Guo, N. Y., Liu, Z., Gan, H. K., Rigopoulos, A., O'Keefe, G. J., Gong, S. J., Goh, Y. W., et al. (2018) · Theranostics · doi:10.7150/thno.25575 · Cited by 62
Hempel, H. A., Cuka, N. S., Kulac, I., Barber, J. R., Cornish, T. C., Platz, E. A., De Marzo, A. M., & Sfanos, K. S. (2017) · The Prostate · doi:10.1002/pros.23280 · Cited by 61
Expression of costimulatory molecule B7-H3 and its prognostic implications in human acute leukemia
Hu, Y., Lv, X., Wu, Y., Xu, J., Wang, L., Chen, W., Zhang, W., Li, J., Zhang, S., & Qiu, H. (2014) · Hematology · doi:10.1179/1607845414y.0000000186 · Cited by 61
B7–H3 as a Prognostic Biomarker and Therapeutic Target in Pediatric central nervous system Tumors
Maachani, U. B., Tosi, U., Pisapia, D. J., Mukherjee, S., Marnell, C. S., Voronina, J. C., Martínez, D., Santi, M., Dahmane, N., Zhou, Z., et al. (2019) · Translational Oncology · doi:10.1016/j.tranon.2019.11.006 · Cited by 60
“Increased levels of B7eH3 in melanoma correlated with activation of JAK2/STAT3/survivin-dependent pathways, which are known to render cancer cells insensitive to chemotherapy and radiation therapy [11,15,17].”
BackgroundT cell coinhibition in prostate cancer: new immune evasion pathways and emerging therapeutics
Barach, Y. S., Lee, J. S., & Zang, X. (2010) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2010.09.006 · Cited by 59
Self-citationEmerging Targets in Cancer Immunotherapy: Beyond CTLA-4 and PD-1
Assal, A., Kaner, J. D., Pendurti, G., & Zang, X. (2015) · Immunotherapy · doi:10.2217/imt.15.78 · Cited by 59
Self-citationYou, G., Lee, Y., Kang, Y., Park, H. W., Park, K., Kim, H., Kim, Y., Kim, S., Kim, J., Moon, D., et al. (2021) · Science Advances · doi:10.1126/sciadv.aax3160 · Cited by 59
B7-H3 in tumors: friend or foe for tumor immunity?
Li, G. L., Quan, Y., Che, F., & Wang, L. (2018) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-017-3508-1 · Cited by 59
Regulation of tumor cell plasticity by the androgen receptor in prostate cancer
Bishop, J. L., Davies, A., Ketola, K., & Zoubeidi, A. (2015) · Endocrine Related Cancer · doi:10.1530/erc-15-0137 · Cited by 59
“Whereas PDL1 on CRPC patient tumors has been difficult to detect or non-existent (Brahmer et al. 2010, Topalian et al. 2012, Taube et al. 2014), the expression of other inhibitory molecules in the B7 family, such as B7H3, correlate with poor prognosis in PCa (Zang et al. 2007).”
BackgroundImmune profiling of pediatric solid tumors
Terry, R. L., Meyran, D., Ziegler, D. S., Haber, M., Ekert, P. G., Trapani, J. A., & Neeson, P. J. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137181 · Cited by 57
“B7-H3 is expressed at higher levels in adult cancers and is associated with a worse prognosis (34, 35).”
BackgroundWang, Q., Ye, Y., Yu, H., Lin, S., Tu, H., Liang, D., Chang, D. W., Huang, M., & Wu, X. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02718-1 · Cited by 56
Immune Checkpoint Therapies in Prostate Cancer
Goswami, S., Aparicio, A. M., & Subudhi, S. K. (2016) · The Cancer Journal · doi:10.1097/ppo.0000000000000176 · Cited by 57
Expression of CD24 and B7-H3 in breast cancer and the clinical significance
Cong, F., Yu, H., & Gao, X. (2017) · Oncology Letters · doi:10.3892/ol.2017.7142 · Cited by 55
Prostate cancer immunotherapy: where are we and where are we going?
Velasco, M. A. D., & Uemura, H. (2017) · Current Opinion in Urology · doi:10.1097/mou.0000000000000462 · Cited by 55
Proctor, D. T., Patel, Z., Lama, S., Resch, L., van Marle, G., & Sutherland, G. R. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1512943 · Cited by 55
“B7-H3 expression has been correlated to poor outcome in patients with non-small cell lung cancer and prostate cancer.(36,39,40) Blocking B7-H3 function has been shown to reduce growth rates of cancer and an anti-B7-H3 mAb, enoblituzumab, was developed and is currently in phase I and II clinical trials for treatment of…”
BackgroundRoles of coinhibitory molecules B7-H3 and B7-H4 in esophageal squamous cell carcinoma
Ling, W., Cao, N., Wang, S., Man, H., Li, P.-F., & Shan, B.-E. (2015) · Tumor Biology · doi:10.1007/s13277-015-4132-5 · Cited by 55
Katayama (2011) · International Journal of Oncology · doi:10.3892/ijo.2011.949 · Cited by 56
Immune checkpoint: The novel target for antitumor therapy
Jiang, X., Liu, G., Li, Y., & Pan, Y. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.12.004 · Cited by 54
“Xingxing Zang’s study showed that strong B7-H3 expression on prostate cancer tumor cells is associated with an increased risk of clinical cancer recurrence and cancer-specific death.(93) In patients with nonsmall cell lung cancer (NSCLC), higher B7-H3 protein levels are also associated with poor survival.”
BackgroundNegative roles of B7-H3 and B7-H4 in the microenvironment of cervical cancer
Han, S., Wang, Y., Shi, X., Zong, L., Liu, L., Zhang, J., Qian, Q., Jin, J., Ma, Y., Cui, B., et al. (2018) · Experimental Cell Research · doi:10.1016/j.yexcr.2018.08.014 · Cited by 53
Lee, H., Kim, J. H., Yang, S. Y., Kong, J., Oh, M., Jeong, D. H., Chung, J., Bae, K. B., Shin, J. Y., Hong, K. H., et al. (2010) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-010-0800-4 · Cited by 52
B7-H4 Expression by Nonhematopoietic Cells in the Tumor Microenvironment Promotes Antitumor Immunity
Rahbar, R., Lin, A., Ghazarian, M., Yau, H. L., Paramathas, S., Lang, P. A., Schildknecht, A., Elford, A. R., Garcia-Batres, C. R., Martin, B. G., et al. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-14-0113 · Cited by 52
Huang, B., Luo, L., Wang, J., He, B., Feng, R., Xian, N., Zhang, Q., Chen, L., & Huang, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1684127 · Cited by 51
B7-H3 was Highly Expressed in Human Primary Hepatocellular Carcinoma and Promoted Tumor Progression
Wang, F., Wang, G., Liu, T., Yu, G., Zhang, G., & Luan, X. (2014) · Cancer Investigation · doi:10.3109/07357907.2014.909826 · Cited by 50
Brignole, C., Calarco, E., Bensa, V., Giusto, E., Perri, P., Ciampi, E., Corrias, M. V., Astigiano, S., Cilli, M., Loo, D., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007174 · Cited by 49
B7-H3 and B7-H4 are independent predictors of a poor prognosis in patients with pancreatic cancer
Xu, H., Chen, X., Tao, M., CHEN, K., CHEN, C., Xu, G., Li, W., YUAN, S., & Mao, Y. (2016) · Oncology Letters · doi:10.3892/ol.2016.4128 · Cited by 49
Chen, X., Wang, L., Wang, W., Zhao, L., & Shan, B. (2016) · Cancer Science · doi:10.1111/cas.12949 · Cited by 49
John, P., Pulanco, M. C., Galbo, P. M., Yao, W., Ohaegbulam, K. C., Zheng, D., & Zang, X. (2022) · Nature Communications · doi:10.1038/s41467-022-30143-8 · Cited by 50
Self-citationKobori, H., Hashiguchi, M., Piao, J., Kato, M., Ritprajak, P., & Azuma, M. (2010) · Immunology · doi:10.1111/j.1365-2567.2009.03236.x · Cited by 49
Ludwig, S., Marczak, Ł., Sharma, P., Abramowicz, A., Gawin, M., Widlak, P., Whiteside, T. L., & Pietrowska, M. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1593808 · Cited by 48
Self-citationAntibody targeting of B7-H4 enhances the immune response in urothelial carcinoma
Podojil, J. R., Glaser, A. P., Baker, D. S., Courtois, E. T., Fantini, D., Yu, Y., Eaton, V. L., Sivajothi, S. K., Chiang, M., Das, A., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2020.1744897 · Cited by 47
“Additionally, more than 90% of endometrial and breast cancers express B7-H4 protein (9), and B7-H4 expression in renal cell carcinoma (10-12), melanoma (13), breast (14), lung (15,16), gastric (17), colorectal (18), pancreatic (19), and prostate (20) cancer are associated with one or more clinicopathological factors,…”
BackgroundHuang, C., Zhou, L., Chang, X., Pang, X., Zhang, H., & Zhang, S. (2016) · Oncology Reports · doi:10.3892/or.2016.4607 · Cited by 46
T cell coinhibition and immunotherapy in human breast cancer.
Janakiram, M., Abadi, Y. M., Sparano, J. A., & Zang, X. (2012) · PubMed · Cited by 46
Self-citationBlocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview
Alme, A., Karir, B. S., Faltas, B. M., & Drake, C. G. (2016) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2016.01.006 · Cited by 45
Regulation of cancer immune escape: The roles of miRNAs in immune checkpoint proteins
Yang, Q., Cao, W., Wang, Z., Zhang, B., & Liu, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2018.05.015 · Cited by 46
B7 score and T cell infiltration stratify immune status in prostate cancer
Zhou, Q., Li, K., Lai, Y., Yao, K., Wang, Q., Zhan, X., Peng, S., Cai, W., Yao, W., Zang, X., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002455 · Cited by 45
“22 However, the correlation between TIICs and B7-H3 has yet to be studied, which perhaps determines the availability of B7-H3 blockers for PCa treatment.”
Self-citationTo kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3
Kanchan, R. K., Doss, D., Κhan, P., Nasser, M. W., & Mahapatra, S. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188783 · Cited by 46
Wang, R., Sun, L., Xia, S., Wu, H., Ma, Y., Zhan, S., Zhang, G., Zhang, X., Shi, T., & Chen, W. (2021) · Cell Death and Disease · doi:10.1038/s41419-021-03736-2 · Cited by 44
Inhibition of B7-H3 reverses oxaliplatin resistance in human colorectal cancer cells
Zhang, P., Chen, Z., Ning, K., Jin, J., & Han, X. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.07.001 · Cited by 43
B7-H3 targeted antibody-based immunotherapy of malignant diseases
Michelakos, T. P., Kontos, F., Barakat, O., Maggs, L., Schwab, J. H., Ferrone, C. R., & Ferrone, S. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1862791 · Cited by 43
“Of the 99 [28-31, 33-37, 39, 43, 45, 46, 49-58, 60-68, 71, 76-123, 124-130] included studies, 92 [28-31, 33-37, 39, 43, 45, 46, 49-57, 60-68, 71, 76-80, 82-105, 108-129, 131] reported frequency of tumor samples with positive B7-H3 protein expression on cancer cells and 61 [2830, 34, 35, 37, 43, 46, 49, 50, 52-56, 62-6…”
Old and New Players of Inflammation and Their Relationship With Cancer Development
Chavez-Dominguez, R., Perez-Medina, M., Aguilar‐Cázares, D., Galicia-Velasco, M., Meneses-Flores, M., Islas-Vázquez, L., Camarena, Á., & López-González, J. S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.722999 · Cited by 43
B7-H4 Mediates Inhibition of T Cell Responses by Activated Murine Hepatic Stellate Cells
Chinnadurai, R., & Grakoui, A. (2010) · Hepatology · doi:10.1002/hep.23953 · Cited by 42
Kreymborg, K., Haak, S., Murali, R., Wei, J., Waitz, R., Gasteiger, G., Savage, P. A., van den Brink, M. R. M., & Allison, J. P. (2015) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0100 · Cited by 43
Self-citationAgarwal, S., Fang, L., McGowen, K. M., Yin, J., Bowman, J., Ku, A. T., Alilin, A. N., Corey, E., Roudier, M. P., True, L. D., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci162148 · Cited by 42
Coexistence of her2, ki67, and p53 in osteosarcoma: A strong prognostic factor
Rahbar, M., Mardanpour, K., & Mardanpour, S. (2016) · North American Journal of Medical Sciences · doi:10.4103/1947-2714.183013 · Cited by 43
Xuan, Y., Sheng, Y., Zhang, D., Zhang, K., Zhang, Z., Yü, P., Wang, S., Shi, X., Lian, J., Liu, K., et al. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101138 · Cited by 42
Xu, Y., Zhang, G., Wang, J., & Hua-cheng, H. (2010) · Saudi Medical Journal · doi:10.15537/1658-3175.5114 · Cited by 42
New Emerging Targets in Cancer Immunotherapy: The Role of B7-H3
Koumprentziotis, I., Theocharopoulos, C., Foteinou, D., Angeli, E., Anastasopoulou, A. N., Gogas, H. J., & Ziogas, D. C. (2024) · Vaccines · doi:10.3390/vaccines12010054 · Cited by 42
“Increased B7-H3 was consistently associated with advanced disease in further studies [161,162,165] and with upregulated expression of androgen receptor ( p = 0.016 [162], p 0.0001 [163]).”
BackgroundInfluentialLi, Y., Zhang, J., Han, S., Qian, Q., Chen, Q., Liu, L., & Zhang, Y. (2017) · Oncology Reports · doi:10.3892/or.2017.5730 · Cited by 41
Grote, S., Ureña-Bailén, G., Chan, K. C.-H., Baden, C., Mezger, M., Handgretinger, R., & Schleicher, S. (2021) · Cells · doi:10.3390/cells10051020 · Cited by 41
“Such overexpression was reported to play a pivotal role in tumor vascularization, metastasis and overall poor clinical prognosis [30,31].”
BackgroundB7-H4 is a prognostic biomarker for poor survival in patients with pancreatic cancer
Shen, L., Qian, Y., Wu, W., Weng, T.-H., Wang, F. X. C., Hong, B., Wu, Z., Wang, Q., Sang, Y., Zhang, H., et al. (2017) · Human Pathology · doi:10.1016/j.humpath.2017.05.023 · Cited by 40
Parker, A. S., Heckman, M. G., Sheinin, Y. M., Wu, K. J., Hilton, T. W., Diehl, N. N., Pisansky, T. M., Schild, S. E., Kwon, E. D., & Buskirk, S. J. (2010) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.01.061 · Cited by 39
Prognostic value of B7-H3 expression in patients with solid tumors: a meta-analysis
Zhang, X., Fang, C., Zhang, G., Jiang, F., Wang, L., & Hou, J. (2017) · Oncotarget · doi:10.18632/oncotarget.21114 · Cited by 38
“Most studies suggested that high levels of B7-H3 expression in tumor cells were associated with disease progression and prognosis [8, 10, 11, 15, 25], but some reported no correlation between B7-H3 expression and tumor prognosis [47, 48].”
BackgroundDeng, M., Wu, D., Zhang, Y., Jin, Z., & Miao, J. (2021) · Gynecologic Oncology · doi:10.1016/j.ygyno.2021.04.013 · Cited by 38
Mendes, A. A. D. A., Lu, J., Kaur, H. B., Zheng, S. L., Xu, J., Hicks, J. L., Weiner, A. B., Schaeffer, E. M., Ross, A. E., Balk, S. P., et al. (2022) · Cancer · doi:10.1002/cncr.34190 · Cited by 38
“Accordingly, several previous studies have demonstrated an association between B7H3 expression and adverse oncologic outcomes in patients with surgically treated PCa, including early prostate- specific antigen (PSA) recurrence 5 as well as the development of castration- resistant PCa (CRPC) and cancerspecific death.(4…”
BackgroundUeno, T., Yeung, M. Y., McGrath, M. M., Yang, S., Zaman, N., Snawder, B., Padera, R. F., Magee, C. N., Gorbatov, R., Hashiguchi, M., et al. (2012) · European Journal of Immunology · doi:10.1002/eji.201242501 · Cited by 38
Li, Z.-Y., Mou, Y., Zhang, X., Chen, Y., Guo, J., Sa'i, S., Yang, Q.-Y., & Chen, Z. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s48085 · Cited by 36
Zanjani, L. S., Madjd, Z., Axcrona, U., Abolhasani, M., Rasti, A., Asgari, M., Fodstad, Ø., & Andersson, Y. (2020) · Annals of Diagnostic Pathology · doi:10.1016/j.anndiagpath.2020.151483 · Cited by 35
PBK phosphorylates MSL1 to elicit epigenetic modulation of CD276 in nasopharyngeal carcinoma
Wang, M.-Y., Qi, B., Wang, F., Lin, Z.-R., Li, M., Yin, W., Zhu, Y.-Y., He, L., Yu, Y., Yang, F., et al. (2021) · Oncogenesis · doi:10.1038/s41389-020-00293-9 · Cited by 36
Serum B7-H4 expression is a significant prognostic indicator for patients with gastric cancer
Shi, H., Ji, M. Q., Wu, J., Zhou, Q., Li, X., Li, Z., Zheng, X. W., Xu, B., Zhao, W., Wu, C., et al. (2014) · World Journal of Surgical Oncology · doi:10.1186/1477-7819-12-188 · Cited by 35
Expression of B7 family checkpoint proteins in cervical cancer
Zong, L., Gu, Y. L., Zhou, Y., Kong, Y., Mo, S., Yu, S., Xiang, Y., & Chen, J. (2021) · Modern Pathology · doi:10.1038/s41379-021-00979-4 · Cited by 34
B7H4 expression in tumor cells impairs CD8 T cell responses and tumor immunity
Zhou, L., Ruan, M., Liu, Y., Zhu, Y., Fu, D., Wu, K., & Zhang, Q. (2019) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-019-02451-4 · Cited by 33
Amori, G., Sugawara, E., Shigematsu, Y., Akiya, M., Kunieda, J., Yuasa, T., Yamamoto, S., Yonese, J., Takeuchi, K., & Inamura, K. (2021) · Prostate Cancer and Prostatic Diseases · doi:10.1038/s41391-021-00331-6 · Cited by 32
Li, C., Sun, Z., Song, Y., & Zhang, Y. (2022) · Cancer Biology & Therapy · doi:10.1080/15384047.2022.2123675 · Cited by 32
Son, Y., Kwon, S., & Cho, J. (2018) · Stem Cells · doi:10.1002/stem.2944 · Cited by 32
Identification of targets for prostate cancer immunotherapy
Papanicolau‐Sengos, A., Yang, Y., Pabla, S., Lenzo, F. L., Kato, S., Kurzrock, R., DePietro, P., Nesline, M., Conroy, J. M., Glenn, S. T., et al. (2019) · The Prostate · doi:10.1002/pros.23756 · Cited by 31
Hempel, H., Heaphy, C. M., Kulaç, İ., Cuka, N. S., Lu, J., Barber, J. R., Marzo, A. M. D., Lotan, T. L., Joshu, C. E., & Sfanos, K. S. (2020) · Cancer Epidemiology Biomarkers & Prevention · doi:10.1158/1055-9965.epi-19-0962 · Cited by 31
Liu, Y., Vlatkovic, L., Sæter, T., Servoll, E., Waaler, G., Nesland, J. M., Giercksky, K.-E., & Axcrona, K. (2012) · International Journal of Urology · doi:10.1111/j.1442-2042.2012.03017.x · Cited by 31
Wu, S., Zhao, X., Du, R., Du, R., Zhu, Q., Fang, H., Zhang, X., Zhang, C., Zheng, W., Yang, J., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.13177 · Cited by 31
Prognostic significance of B7-H3 expression in patients with colorectal cancer: A meta-analysis
Fan, H., Zhu, J., & Yao, X. (2016) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.326.11511 · Cited by 31
Kgatle, M., Boshomane, T. M. G., Lawal, I. O., Mokoala, K. M. G., Mokgoro, N. P., Lourens, N., Kairemo, K., Zeevaart, J. R., Vorster, M., & Sathekge, M. M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084109 · Cited by 32
Interstitial Infusion of Glioma-Targeted Recombinant Immunotoxin 8H9scFv-PE38
Luther, N., Cheung, N. V., Souliopoulos, E. P., Karempelas, I., Bassiri, D., Edgar, M. A., Guo, H.-F., Pastan, I. H., Gutin, P. H., & Souweidane, M. M. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0996 · Cited by 31
“Expression of this protein may contribute to tumor resistance to host defenses and has in fact been implicated with tumor aggressiveness in prostate and renal cell carcinoma (22, 23).”
BackgroundFan, M., Zhuang, Q., Chen, Y., Ding, T., Yao, H., Chen, L., He, X., & Xu, X. (2014) · PubMed · Cited by 30
Cao, D., Chen, M., Zhang, Q.-F., Zhou, Y.-F., Zhang, M., Mai, S., Zhang, Y., Chen, M., Li, X., & Wang, H. (2020) · Aging · doi:10.18632/aging.103395 · Cited by 30
Nunes‐Xavier, C. E., Kildal, W., Kleppe, A., Danielsen, H. E., Wæhre, H., Llarena, R., Mælandsmo, G. M., Fodstad, Ø., Pulido, R., & Lopez, J. I. (2021) · The Prostate · doi:10.1002/pros.24180 · Cited by 30
Leung, J., & Suh, W. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1201242 · Cited by 30
Desidero, T. D., Derosa, L., Galli, L., Orlandi, P., Fontana, A., Fioravanti, A., Marconcini, R., Gıorgı, M., Campi, B., Saba, A., et al. (2016) · Investigational New Drugs · doi:10.1007/s10637-016-0385-0 · Cited by 30
B7-H3 is spliced by SRSF3 in colorectal cancer
Zhang, C., Chen, Y., Li, F., Yang, M. G., Meng, F., Zhang, Y., Chen, W., & Wang, W. (2020) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02683-9 · Cited by 30
CD276 as a novel CAR NK‐92 therapeutic target for neuroblastoma
Grote, S., Chan, K. C.-H., Baden, C., Bösmüller, H. C., Sulyok, M., Frauenfeld, L., Ebinger, M., Handgretinger, R., & Schleicher, S. (2020) · Advances in Cell and Gene Therapy · doi:10.1002/acg2.105 · Cited by 30
Possible involvement of soluble B7-H4 in T cell-mediated inflammatory immune responses
Kamimura, Y., Kobori, H., Piao, J., Hashiguchi, M., Matsumoto, K., Hirose, S., & Azuma, M. (2009) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2009.08.144 · Cited by 30
Immune checkpoint blockade therapy for bladder cancer treatment
Kim, J. (2016) · Korean journal of urology · doi:10.4111/icu.2016.57.s1.s98 · Cited by 30
T Lymphocyte–Based Cancer Immunotherapeutics
Borrie, A. E., & Vareki, S. M. (2018) · International review of cytology · doi:10.1016/bs.ircmb.2018.05.010 · Cited by 29
Spatial whole transcriptome profiling of primary tumor from patients with metastatic prostate cancer
Salachan, P. V., Rasmussen, M. K., Ulhøi, B. P., Jensen, J. B., Borre, M., & Sørensen, K. D. (2023) · International Journal of Cancer · doi:10.1002/ijc.34708 · Cited by 29
“41,42 Using ST, a previous study 25 observed high expression of CD276 in PCa metastases suggesting alternate routes for immunotherapy.”
BackgroundExpression and Significance of Immune Checkpoints in Clear Cell Carcinoma of the Uterine Cervix
Zong, L., Zhang, Q., Zhou, Y., Kong, Y., Yu, S., Chen, J., Zhang, Y., & Xiang, Y. (2020) · Journal of Immunology Research · doi:10.1155/2020/1283632 · Cited by 29
“Samples were considered positive for B7-H3 and B7-H4 when ≥ 5% of the TCs expressing these proteins at any intensity; the 5% cut-o ff was chosen based on a previous publication [15].”
Coinhibitory molecules in cancer biology and therapy
Mocellin, S., Benna, C., & Pilati, P. (2013) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2013.01.003 · Cited by 29
“of a range of tumors, such as renal [142], prostate [146], esophageal [147] and gastric [148] carcinomas as well as melanoma [149].”
BackgroundBarabé, F., Gil, L., Celton, M., Bergeron, A., Lamontagne, V., Roques, É., Lagacé, K., Forest, A., Johnson, R. M., Pécheux, L., et al. (2016) · Leukemia · doi:10.1038/leu.2016.302 · Cited by 28
Ohaegbulam, K. C., Liu, W., Jeon, H., Almo, S. C., & Zang, X. (2017) · Oncotarget · doi:10.18632/oncotarget.21098 · Cited by 27
Self-citation
Metadata
- Authors
- Zang, X., Thompson, R. H., Al-Ahmadie, H. A., Serio, A. M., Reuter, V. E., Eastham, J. A., Scardino, P. T., Sharma, P., & Allison, J. P.
- Affiliations
- Howard Hughes Medical Institute (US)
- University of Chicago Medical Center (US)
- Pathology, and
- Memorial Sloan Kettering Cancer Center (US)
- The University of Texas MD Anderson Cancer Center (US)
- Corresponding author
- Allison, James P.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2007-12-04
- Volume
- 104
- Issue
- 49
- Pages
- 19458-19463
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC2148311
- OpenAlex
- W2164079212
- Cited by
- 401
- References
- 42
- Citations by year
- 2026: 20 · 2025: 15 · 2024: 20 · 2023: 23 · 2022: 27 · 2021: 28 · 2020: 22 · 2019: 19 · 2018: 21 · 2017: 26 · 2016: 31 · 2015: 15 · 2014: 22 · 2013: 25 · 2012: 27
- FWCI
- 11.81
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Cancer Research Institute
- Prostate Cancer Foundation
- National Cancer Institute (T32CA082088)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
- Keywords
- B7-H3, prostate cancer, B7/CD28 family, tumor immune evasion, tumor recurrence, cancer-specific mortality, lymph node metastasis, prognostic factors, immunotherapy targets, radical prostatectomy
- MeSH terms
- Humans, Immunohistochemistry, Male, Prognosis, Prostatic Neoplasms, Receptors, Immunologic, Antigens, CD, Survival Analysis, B7-1 Antigen, Disease Progression, B7 Antigens, V-Set Domain-Containing T-Cell Activation Inhibitor 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.